Amgen Announced Data At 52 Weeks In Phase 2 Study With MariTide (Maridebart Cafraglutide, Formerly AMG 133) Subcutaneously Administered Monthly Or Less Frequently, Showing Up To ~20% Average Weight Loss At Week 52 Without A Weight Loss Plateau
Amgen Announced Data At 52 Weeks In Phase 2 Study With MariTide (Maridebart Cafraglutide, Formerly AMG 133) Subcutaneously Administered Monthly Or Less Frequently, Showing Up To ~20% Average Weight Loss At Week 52 Without A Weight Loss Plateau
安進在對MariTide（原名AMG 133）進行的二期研究中公佈了52周的數據，該藥物以皮下注射方式每月或更少頻率給藥，顯示在第52周時平均體重減輕約20%，且沒有減重平台期。
- MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight
- MariTide is the First Obesity Treatment With Monthly or Less Frequent Dosing to Demonstrate Safe and Effective Weight Loss in a Phase 2 Study
- In People With Type 2 Diabetes Living With Obesity or Overweight MariTide Demonstrated up to ~17% Average Weight Loss Without a Weight Loss Plateau and Lowered Average HbA1c by up to 2.2 Percentage Points at 52 Weeks
- MariTide Delivered Substantial Improvements Across Cardiometabolic Parameters
- Amgen Announces "MARITIME," a Phase 3 Clinical Development Program in Obesity and Obesity-Related Conditions
- MariTide在肥胖或超重人群中展示了長達52周的平均體重減輕高達~20%，且沒有體重減輕停滯現象。
- MariTide是首個通過每月或更少頻繁給藥方式證明在2期研究中安全有效減重的肥胖治療方法。
- 在肥胖或超重的2型糖尿病患者中，MariTide在52周內展示了高達~17%的平均體重減輕，沒有體重減輕停滯現象，並且將平均糖化血紅蛋白水平降低了最高2.2個百分點。
- MariTide在心臟代謝參數方面取得了顯著改善。
- 安進宣佈"MARITIME"，這是一項針對肥胖及與肥胖相關疾病的3期臨床開發計劃。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間